Nothing said here yet.
to join the conversation.
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sell | 50,246 | $1.3M | Wed, Sep 30 |
| Davidson Michael H.Chief Executive Officer | Buy | 10,000 | $226.5K | Mon, Sep 14 |
| Smither John WDirector | Sell | 1,600 | $40.5K | Fri, Sep 4 |
| Kastelein Johannes Jacob PieterChief Scientific Officer | Sell | 125,000 | $3.4M | Mon, Aug 24 |
NewAmsterdam Pharma recently dosed the first participant in SPINOZA, a Phase 2b, randomized, double-blind, placebo-controlled trial evaluating its CETP inhibitor obicetrapib in about 400 people with preclinical Alzheimer’s disease.
- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms-
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® (obicetrapib en monoterapia) y Evlarco® (combinación a dosis fija de obicetrapib y ezetimiba) - Aprobación de un fármaco pionero en su clase respaldada por los…
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) has cleared a major regulatory hurdle. On September 21, it announced European Commission approval of Ubeslo, containing 10 mg of obicetrapib, and Evlarco, combining 10 mg of obicetrapib with 10 mg of ezetimibe.
- Homologation d'une thérapie novatrice appuyée par les essais de phase 3 BROADWAY, BROOKLYN et TANDEM, ayant démontré des réductions significatives du LDL-C associées à un profil de tolérance favorable - - La première approbation réglementaire mondiale…
– Zulassung als „First-in-Class"-Präparat stützt sich auf die Phase-3-Studien BROADWAY, BROOKLYN und TANDEM, die eine signifikante Senkung des LDL-C-Spiegels bei gutem Verträglichkeitsprofil belegen – – Erste weltweite Zulassung von Obicetrapib stellt einen…
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile - - First global regulatory approval of obicetrapib marks a defining milestone for NewAmsterdam…
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerability profile-
NewAmsterdam Pharma has delivered a powerful long term share price gain, yet the recent pullback raises a sharper question for investors about how its current market value lines up with the company’s book value.